Kalman syndrome, also known as “idiopathic hypogonadotropic hypogonadism (IHH)” in men, is associated with loss of smell or reduced sense of smell, due to a congenital abnormality in the hypothalamus, the “commander” of endocrine hormone production in the body. Due to congenital abnormalities in the hypothalamus, it cannot correctly issue orders to the testes to develop and secrete androgens, resulting in delayed puberty, sexual infantilism, inability to have sex and infertility, and long-term lack of androgens in the body can lead to osteoporosis, diabetes and cardiovascular disease, which can endanger health and affect life expectancy. Patients with Kalman syndrome have a normal chromosome of 46XY and normal endocrine function, and they look like normal people, even taller than normal people, but the lack of androgens makes them less muscular and less strong. Kalman syndrome is one of the most common abnormalities in sexual development, with a prevalence of about 1/2000 in men, but most patients do not receive good guidance and treatment for various reasons. In fact, Kalman syndrome can become a real man with timely and proper treatment, and it is possible to have fertility with some special treatments. Medication is very effective and needs to be maintained for at least about two years with the possibility of restoring fertility. At present, the main objectives of treatment for male IHH patients are: 1) to restore sexual function, improve libido, and enhance the quality of sexual life; 2) to promote and maintain the development of secondary sexual characteristics; 3) to restore fertility; and 4) to improve bone density. The treatment means are hormone replacement methods, including GnRH pulse therapy, gonadotropin therapy and sex hormone replacement.